Resmed Inc

RMD remains in a Stage 4 decline with a clear sequence of lower highs and lower lows below declining EMAs, confirming a bearish medium-term bias. Short-term timing is neutral as price is tightly tracking the flattening 9/21 EMA cluster with no exhaustion signals, making fresh sell entries unfavorable. Execution should be deferred and conducted by trimming into supply on rallies into the 9/21/50 EMA zone and recent breakdown resistance.

• ↑11% YoY revenue growth to $1.43B in Q3 FY2026
• ↑Non-GAAP EPS rose 21% YoY; operating margin at 36.7%
• ↓SG&A expenses rose 14% YoY; expect 19–20% of revenue in FY2026